Quarterly report pursuant to Section 13 or 15(d)

Basis of Presentation and Summary of Significant Accounting Policies (Details Narrative)

v3.22.2
Basis of Presentation and Summary of Significant Accounting Policies (Details Narrative) - USD ($)
 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Dec. 31, 2021
Research And Development Expenses $ 3,300,000 $ 2,900,000  
Deferred Revenue 10,000,000.0    
Cash and cash equivalents 16,700,000    
Amount held in money markey account 10,200,000    
Accounts Receivable $ 8,489   $ 12,510
Warrants And Options [Member]      
Potentially Dilutive Securities Excluded From The Computation Of Eps 6,460,018